Meropenem Acs Dobfar (Meropenem Anhydrous)

Meropenem, the active ingredient in Meropenem Acs Dobfar, is a carbapenem presented as an injectable solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, bacterial meningitis, severe sepsis, and hospital‑acquired pneumonia in hospitalized patients.

GNH USA supplies Meropenem Acs Dobfar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a carbapenem antibiotic used to treat serious infections caused by susceptible bacteria.

- Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure in patients with severe intra‑abdominal infections. - Complicated urinary tract infections: provides effective bacterial clearance and symptom resolution in complicated UTIs. - Bacterial meningitis: penetrates the cerebrospinal fluid to eradicate causative organisms and improve outcomes. - Severe sepsis: offers broad‑spectrum coverage to control systemic infection and reduce mortality. - Hospital‑acquired pneumonia: treats resistant Gram‑negative and Gram‑positive pathogens in ventilated patients.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruptions. - Headache: transient cranial discomfort. - Infusion site reactions: pain, erythema, or phlebitis at the injection site. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or high doses. - Anaphylaxis: acute, potentially life‑threatening allergic reaction. - Clostridioides difficile infection: severe colitis due to gut flora disruption. - Renal toxicity: worsening kidney function in susceptible individuals. - Neutropenia: marked reduction in neutrophil count. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Careful assessment and monitoring are required before and during therapy. - Renal function: adjust dosing in patients with impaired renal clearance. - Neurological status: monitor for seizures, particularly in patients with CNS disorders. - Allergy history: avoid use in individuals with known hypersensitivity to carbapenems or β‑lactams. - Concomitant antibiotics: evaluate for overlapping toxicities and potential antagonism. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly indicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Valproic acid: carbapenems can lower valproate levels, risking loss of seizure control. - Other carbapenems: concurrent use may increase toxicity without added benefit. - Nephrotoxic agents: combined use can exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Loop diuretics: may increase risk of ototoxicity. - Aminoglycosides: monitor renal function for additive nephrotoxicity. - Warfarin: possible increase in INR; frequent coagulation monitoring advised. - Oral contraceptives: efficacy may be reduced; advise alternative contraception.